This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Comparison of Patch vs. Pill Estrogen Therapy on Testosterone Levels and Thyroid Tests in Menopausal Women

This study has been completed.
Massachusetts General Hospital
Information provided by (Responsible Party):
Watson Pharmaceuticals Identifier:
First received: September 14, 2005
Last updated: October 11, 2012
Last verified: October 2012
This study compares the effects of 12 weeks of treatment with transdermal versus oral estrogen therapy on testsoterone levels and thyroid tests in healthy, naturally menopausal women.

Condition Intervention Phase
Menopause Drug: Premarin® (oral) vs. Alora® (transdermal) Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Comparison of Transdermal vs. Oral Estrogen Replacement Therapy on Androgen Levels and Thyroid Function in Naturally Menopausal Women

Resource links provided by NLM:

Further study details as provided by Watson Pharmaceuticals:

Primary Outcome Measures:
  • Compare the effects of a 12-week course of oral CEE to a 12-week course of transdermal estradiol on free testosterone concentrations in menopausal women. [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • Compare the effects of oral versus transdermal ERT on thyroid binding globulin concentrations and tests of thyroid function. [ Time Frame: 12 weeks ]
  • Compare the effects of oral versus transdermal ERT on cortisol binding globulin and total and free cortisol concentrations. [ Time Frame: 12 weeks ]

Enrollment: 27
Study Start Date: January 2002
Primary Completion Date: May 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sequence A
Oral ERT then transdermal ERT
Drug: Premarin® (oral) vs. Alora® (transdermal)
Experimental: Sequence B
Transdermal ERT then oral ERT
Drug: Premarin® (oral) vs. Alora® (transdermal)


Ages Eligible for Study:   42 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy
  • Naturally menopausal women
  • Aged 42-70 years
  • Currently using combination estrogen-progestin replacement therapy

Exclusion Criteria:

  • Women with contraindications to HRT use, including:Unexplained vaginal bleeding, liver disease, breast or endometrial cancer, venous thromboembolic events
  • Thyroid disease
  • Adrenal disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00224094

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Watson Pharmaceuticals
Massachusetts General Hospital
Principal Investigator: Jan L Shifren, MD Massachusetts General Hospital
  More Information

Responsible Party: Watson Pharmaceuticals Identifier: NCT00224094     History of Changes
Other Study ID Numbers: ALO0102
Study First Received: September 14, 2005
Last Updated: October 11, 2012

Keywords provided by Watson Pharmaceuticals:
Sex Hormone Binding Globulin
Thyroid function

Additional relevant MeSH terms:
Estrogens, Conjugated (USP)
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on September 21, 2017